Last reviewed · How we verify
Bevacizumab + Pemetrexed
Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while pemetrexed inhibits folate-dependent enzymes to disrupt DNA synthesis and cell division.
Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while pemetrexed inhibits folate-dependent enzymes to disrupt DNA synthesis and cell division. Used for Non-squamous non-small cell lung cancer (NSCLC), Mesothelioma.
At a glance
| Generic name | Bevacizumab + Pemetrexed |
|---|---|
| Also known as | Avastin®, ALIMTA® |
| Sponsor | PD Dr. med. Wolfgang Schuette |
| Drug class | Monoclonal antibody + antifolate antimetabolite combination |
| Target | VEGF (bevacizumab); folate-dependent enzymes (pemetrexed) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors require for growth. Pemetrexed is an antifolate antimetabolite that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, disrupting nucleotide synthesis and inducing apoptosis. Together, they provide complementary mechanisms targeting tumor vasculature and cancer cell proliferation.
Approved indications
- Non-squamous non-small cell lung cancer (NSCLC)
- Mesothelioma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea/vomiting
- Hypertension
- Proteinuria
- Bleeding
Key clinical trials
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
- Pan Tumor Rollover Study (PHASE2)
- SYS6090 Combination Therapy in Advanced Lung Cancer (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs (PHASE2)
- Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab + Pemetrexed CI brief — competitive landscape report
- Bevacizumab + Pemetrexed updates RSS · CI watch RSS
- PD Dr. med. Wolfgang Schuette portfolio CI